Author(s): Bader AG, Kang S, Zhao L, Vogt PK
Abstract Share this page
Abstract There have long been indications of a role for PI3K (phosphatidylinositol 3-kinase) in cancer pathogenesis. Experimental data document a requirement for deregulation of both transcription and translation in PI3K-mediated oncogenic transformation. The recent discoveries of cancer-specific mutations in PIK3CA, the gene that encodes the catalytic subunit p110alpha of PI3K, have heightened the interest in the oncogenic potential of this lipid kinase and have made p110alpha an ideal drug target.
This article was published in Nat Rev Cancer
and referenced in Journal of Medical Diagnostic Methods